Geode Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Geode Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-183,207	Closed	-$24.1M	–	4526
2020 Q4	$24.1M	Buy	183,207 +10,633	+6%	+$940K	﹤0.01%	1601
2020 Q3	$8.72M	Buy	172,574 +27,226	+19%	+$1.22M	﹤0.01%	2028
2020 Q2	$6.93M	Buy	145,348 +3,805	+3%	+$177K	﹤0.01%	2150
2020 Q1	$6.93M	Buy	141,543 +19,238	+16%	+$980K	﹤0.01%	1950
2019 Q4	$7.02M	Buy	122,305 +2,237	+2%	+$111K	﹤0.01%	2246
2019 Q3	$4.32M	Sell	120,068 -3,707	-3%	-$145K	﹤0.01%	2467
2019 Q2	$3.85M	Sell	123,775 -1,488	-1%	-$40.3K	﹤0.01%	2556
2019 Q1	$2.94M	Buy	125,263 +45,242	+57%	+$726K	﹤0.01%	2617
2018 Q4	$1.1M	Buy	80,021 +48,659	+155%	+$614K	﹤0.01%	3076
2018 Q3	$312K	Buy	+31,362	New	+$515K	﹤0.01%	3616

Geode Capital Management's EIDX Position: Q1 2021 in Review

Geode Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 183,207 shares — an estimated $24.1M sold.

Geode Capital Management first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $24.1M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Geode Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Geode Capital Management sold 183,207 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $24.1M.
Geode Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
Geode Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $24.1M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Geode Capital Management's 13F filing for Q1 2021, filed 12 May 2021.